<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03137784</url>
  </required_header>
  <id_info>
    <org_study_id>CQVM149B2204</org_study_id>
    <nct_id>NCT03137784</nct_id>
  </id_info>
  <brief_title>Bronchodilator Effects and Safety of Glycopyrronium Bromide (25 ug and 50 ug o.d.) in Asthma</brief_title>
  <official_title>A Multicenter, Randomized, Double-blind, Placebo-controlled 3-period Complete Cross-over Study to Assess the Bronchodilator Effects and Safety of Glycopyrronium Bromide (NVA237) (25 ug and 50 ug o.d.) in Asthma Patients.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this trial is to characterize the bronchodilator effects and safety of 25 ug
      and 50 ug o.d. NVA237 (glycopyrronium bromide) doses compared to placebo in asthma patients
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study uses a randomized, double-blind, placebo controlled, 3-period cross-over clinical
      trial design. During a screening epoch patient eligibility will be assessed. The screening
      epoch will be followed by a 21-day Run-in epoch during which patients will continue their
      inhaled corticosteroids use but be withdrawn from LABA-treatment and switched to short-acting
      bronchodilator-rescue medication. After the Run-in period patients will be randomized to one
      of the 6 treatment sequences and enter the first 7-day study treatment period. Treatment
      period one is followed by a 10 to 14 days washout period after which patients begin the
      second 7-day treatment period which is then followed by a second 10 to 14 days washout period
      followed by the third 7-day treatment period. At the end of each treatment period spirometry
      will be performed to assess the primary endpoint in terms of trough FEV1. The study
      population will consist of approximately 144 patients with asthma who have been treated in a
      stable regimen of ICS/LABA for at least 4 weeks prior to screening.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 4, 2017</start_date>
  <completion_date type="Actual">December 29, 2017</completion_date>
  <primary_completion_date type="Actual">December 29, 2017</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Trough FEV1</measure>
    <time_frame>Following 1 week of treatment</time_frame>
    <description>To evaluate the bronchodilator effects of NVA237 (25 ug and 50 ug) compared to placebo in terms of trough FEV1 (mean of 23h 15 min and 23 h 45 min post -dose) following 1 week of treatment in the respective treatment period</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>FEV1 AUC</measure>
    <time_frame>Following 1 week of treatment</time_frame>
    <description>To evaluate the bronchodilator effects of NVA237 (25 ug and 50 ug) compared with placebo in terms of Standardized FEV1 AUC following 1 week of treatment in the respective treatment period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak FEV1</measure>
    <time_frame>Following 1 week of treatment</time_frame>
    <description>To evaluate the bronchodilator effects of NVA237 (25 ug and 50 ug) compared with placebo in terms of Peak FEV1 following 1 week of treatment in the respective treatment period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FEV1</measure>
    <time_frame>Following 1 week of treatment</time_frame>
    <description>To evaluate the bronchodilator effects of NVA237 (25 ug and 50 ug) compared with placebo in terms of FEV1 following 1 week of treatment in the respective treatment period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient diary data</measure>
    <time_frame>Following 1 week of treatment</time_frame>
    <description>To evaluate the bronchodilator effects of NVA237 (25 ug and 50 ug) compared with placebo as determined by patient diary data in the respective treatment period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FVC</measure>
    <time_frame>Following 1 week of treatment</time_frame>
    <description>To evaluate the bronchodilator effects of NVA237 (25 ug and 50 ug) compared with placebo in terms of FVC following 1 week of treatment in respective treatment period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FEV1/FVC ratio</measure>
    <time_frame>Following 1 week of treatment</time_frame>
    <description>To evaluate the bronchodilator effects of NVA237 (25 ug and 50 ug) compared with placebo in terms of FEV1/FVC ratio following 1 week of treatment in respective treatment period</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">148</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>1(NVA237 50 ug/NVA237 25 ug/placebo)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Treatment sequence: NVA 237 50 ug, 25 ug and placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2(NVA237 50 ug/placebo/NVA237 25 ug)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Treatment sequence: NVA 237 50 ug, placebo and 25 ug</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3 (NVA237 25 ug/NVA237 50 ug/placebo)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Treatment sequence: NVA237 25 ug, 50 ug and placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4 (NVA237 25 ug/placebo/NVA237 50 ug)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Treatment sequence: NVA 237 25 ug, placebo and 50 ug</description>
  </arm_group>
  <arm_group>
    <arm_group_label>5 (placebo/NVA237 50 ug/ NVA237 25 ug)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Treatment sequence: Placebo, NVA237 50 ug and 25 ug</description>
  </arm_group>
  <arm_group>
    <arm_group_label>6 (placebo/ NVA237 25 ug/NVA237 50 ug)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Treatment sequence: placebo, NVA237 25 ug and 50 ug</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NVA237 (glycopyrronium bromide)</intervention_name>
    <description>In each treatment arm, patient will receive NVA237 (glycopyrronium bromide) 25 ug and 50 ug dose</description>
    <arm_group_label>1(NVA237 50 ug/NVA237 25 ug/placebo)</arm_group_label>
    <arm_group_label>2(NVA237 50 ug/placebo/NVA237 25 ug)</arm_group_label>
    <arm_group_label>3 (NVA237 25 ug/NVA237 50 ug/placebo)</arm_group_label>
    <arm_group_label>4 (NVA237 25 ug/placebo/NVA237 50 ug)</arm_group_label>
    <arm_group_label>5 (placebo/NVA237 50 ug/ NVA237 25 ug)</arm_group_label>
    <arm_group_label>6 (placebo/ NVA237 25 ug/NVA237 50 ug)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>In each treatment arm, patient will receive placebo</description>
    <arm_group_label>1(NVA237 50 ug/NVA237 25 ug/placebo)</arm_group_label>
    <arm_group_label>2(NVA237 50 ug/placebo/NVA237 25 ug)</arm_group_label>
    <arm_group_label>3 (NVA237 25 ug/NVA237 50 ug/placebo)</arm_group_label>
    <arm_group_label>4 (NVA237 25 ug/placebo/NVA237 50 ug)</arm_group_label>
    <arm_group_label>5 (placebo/NVA237 50 ug/ NVA237 25 ug)</arm_group_label>
    <arm_group_label>6 (placebo/ NVA237 25 ug/NVA237 50 ug)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and female adult patients aged &gt;= 18 or =&lt; 65 years

          -  Patients with a diagnosis of asthma for a period of at least 1 year receiving daily
             treatment of ICS/LABA in a stable regimen for &gt;= 4 weeks

          -  Pre-bronchodilator FEV1 of &gt;= 50% and =&lt; 80% of the predicted normal value and an
             increase in FEV1 of 12% and &gt;= 200 ml during reversibility testing

        Key Exclusion Criteria:

          -  Patients who have had an asthma exacerbation that required either treatment with
             systemic corticosteroids for at least 3 days, or an emergency room visit, or hospital
             treatment within 6 weeks prior to screening and patients with a history of
             life-threatening asthma attacks

          -  Patients who have had a respiratory tract infection within 4 weeks prior to screening.

          -  Patients who have smoked or inhaled tobacco products within the past 6 month of
             screening.

          -  Patients with a history of chronic lung diseases other than asthma, including (but not
             limited to) chronic obstructive pulmonary disease, bronchiectasis, sarcoidosis,
             interstitial lung disease, cystic fibrosis, and tuberculosis (unless tuberculosis is
             confirmed as no longer active by imaging).

          -  Patients on Maintenance Immunotherapy (desensitization) for allergies for at least 3
             months prior to Run-in who are expected to change therapy throughout the course of the
             study.

          -  Patients who during the Run-in period are shown to be intolerable to LABA withdrawal.

          -  Patients who have discontinued LAMA therapy in the past (e.g. due to intolerance or
             perceived lack of efficacy).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>North Dartmouth</city>
        <state>Massachusetts</state>
        <zip>02747</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63141</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Skillman</city>
        <state>New Jersey</state>
        <zip>08558</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27607</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Medford</city>
        <state>Oregon</state>
        <zip>97504</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>El Paso</city>
        <state>Texas</state>
        <zip>79903</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Erpent</city>
        <zip>5100</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hasselt</city>
        <zip>3500</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Mechelen</city>
        <zip>2800</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Berlin</city>
        <zip>10119</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Frankfurt</city>
        <zip>60596</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Grosshansdorf</city>
        <zip>22927</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lubeck</city>
        <zip>23552</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Wiesbaden</city>
        <zip>65187</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Shinjuku-ku</city>
        <state>Tokyo</state>
        <zip>169-0073</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Toshima-ku</city>
        <state>Tokyo</state>
        <zip>171-0014</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Daugavpils</city>
        <state>LVA</state>
        <zip>LV-5417</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Riga</city>
        <zip>LV 1002</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Riga</city>
        <zip>LV-1038</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Klaipeda</city>
        <zip>LT-92231</zip>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Klaipeda</city>
        <zip>LT-92288</zip>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Germany</country>
    <country>Japan</country>
    <country>Latvia</country>
    <country>Lithuania</country>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 24, 2017</study_first_submitted>
  <study_first_submitted_qc>April 28, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 3, 2017</study_first_posted>
  <last_update_submitted>February 13, 2018</last_update_submitted>
  <last_update_submitted_qc>February 13, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 15, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>asthma,</keyword>
  <keyword>NVA237,</keyword>
  <keyword>glycopyrronium bromide</keyword>
  <keyword>allergic asthma,</keyword>
  <keyword>allergy triggered asthma,</keyword>
  <keyword>reactive asthma,</keyword>
  <keyword>asthma attack,</keyword>
  <keyword>difficulty breathing</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bromides</mesh_term>
    <mesh_term>Bronchodilator Agents</mesh_term>
    <mesh_term>Glycopyrrolate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

